VivoSeq
Neurology

Complex Regional Pain Syndrome

21

Pipeline Programs↗

5

Active Trials↗

14

Companies Involved↗

Complex Regional Pain Syndrome is an emerging landscape with 21 programs across 14 companies. The most active players are Takeda, Pfizer, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 5 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

11/100

Mech. Concentration

17/100

Completion Rate

54/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2I

Imclone

1 program

Phase 2P

Parkedale

1 program

Phase 2P

Pascoe Pharmazeutische Praeparate GmbH

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

33 of 34 classified programs — the dominant modality here.

3%ALL OTHERSMonoclonal antibody13%

Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 100% of 34 pipeline programs.

Analysis

Trial Status

26

clinical trials

Unknown status8 · 31%
Completed7 · 27%
Terminated6 · 23%
Recruiting4 · 15%
Enrolling by invitation1 · 4%

Clinical Trials

Trial Activity

26 trials

The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome
Recruiting·UUniversity of California, San Diego·Phase 1·NCT06393101·52 enrolled
The Effectiveness of Conservative Treatment in Patients With Complex Regional Pain Syndrome.
Recruiting·OOulu University Hospital·N/A·NCT07208825·156 enrolled
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
Recruiting·SStanford University·N/A·NCT02502162·120 enrolled
Perineural Incobotulinumtoxin-A for Complex Regional Pain Syndrome - An Open-label Feasibility Study
Recruiting·—·N/A·NCT07473635·20 enrolled
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
Enrolling by invitation·HHospital for Special Surgery, New York·Phase 4·NCT06306157·40 enrolled
A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1
Completed·MMayo Clinic·Phase 3·NCT00166452·7 enrolled
Evaluation of the Physiodoloris Pain Monitor in Patients With Complex Regional Pain Syndrome
Completed·HHopital Foch·N/A·NCT02663284·30 enrolled
Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS)
Completed·Takeda logoTakeda·Phase 2·NCT03990649·24 enrolled
A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT00067743·40 enrolled
Nitrous Oxide for the Treatment of Complex Regional Pain Syndrome
Completed·TThe Cleveland Clinic·Phase 3·NCT03879538·44 enrolled
A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT01008553·258 enrolled
Effectiveness of Ketamine Administered by Mesotherapy in Complex Regional Pain Syndrome Type 1 (CRPS1)
Completed·HHospices Civils de Lyon·Phase 2/3·NCT04650074·31 enrolled
Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS)
Terminated·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2·NCT00689585·4 enrolled
Randomized Controlled Trial of Ketamine Infusion With Continuous Epidural Infusion for Treatment of Complex Regional Pain Syndrome
Terminated·HHospital for Special Surgery, New York·Phase 2·NCT02094352·3 enrolled
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1
Terminated·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT00109772·184 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)